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Vitamin K has an important role in regulating bone mineralization and preventing vascular calcification [5] . It is involved in the carboxylation of glutamate residues in vitamin K-dependent proteins to form gamma-carboxyglutamate residues (Gla residues) that are essential for binding calcium. Vitamin K-dependent proteins with Gla domains play a role in three important physiological processes, which are blood clotting, bone metabolism, and vascular biology. Previously, recommendations about the dietary vitamin K intake have been based on hepatic requirements for the synthesis of clotting factors. However, these studies suggested that bone metabolism and vascular wall-related processes require a higher dietary intake of vitamin K [6, 7] . In hemodialysis patients, the vitamin K level is significantly lower than in healthy populations, and the fracture rate increases as vitamin K decreases [8] .
We previously reported that oral administration of vitamin K 2 -induced changes of bone metabolism markers in hemodialysis patients who had low serum intact PTH levels without causing side effects such as A-V fistula obstruction and infarction, suggesting that vitamin K 2 therapy could safely improve bone remodeling [9] . However, our previous study had no control group. Therefore, the present controlled study was performed to investigate the effect of vitamin K 2 on bone metabolism markers and osteoprotegerin (OPG) in hemodialysis patients with a low serum intact PTH level.
Materials and Methods

Subjects
We enrolled 40 Japanese patients who had been on hemodialysis for over 2 years at the Onomichi Clinic (Onomichi, Japan), Hakuai Clinic (Kure, Japan), Chuonaika Clinic (Kure, Japan), Clear Yakeyama Clinic (Kure, Japan), or Harada Hospital (Hiroshima, Japan). In all patients, intact PTH level was ! 100 pg/ml at 12 months, 6 months, and just before the present study. This inclusion criterion was selected because intact PTH ! 100 pg/ml corresponds to the cut-off value for adynamic bone disease according to K/DOQI guideline 13C [10] . The study began in April 2004 and was completed in January 2007. All patients who participated gave written informed consent. This study was conducted in accordance with the Declaration of Helsinki, and its protocol was approved by ethical committee of Hiroshima university faculty of medicine and other institutes. All of the subjects were clinically stable and had no acute infection. We excluded patients who had undergone parathyroidectomy and patients who had been treated with vitamin K antagonists or active vitamin D metabolites. The subjects were randomly assigned to a vitamin K 2 group that was treated with menatetrenone (45 mg/day) for 12 months (n = 22) or a control group that received conventional therapy without menatetrenone (n = 18). No patient received vitamin D therapy during study period, but oral administration of calcium carbonate and sevelamer hydrochloride was not regulated by the protocol. The calcium concentration of the dialysate used for hemodialysis was 3.0 mEq/l and was not changed during this study. Thirty-three patients completed the follow-up period. In the vitamin K 2 group, 9 men and 11 women completed the study. The underlying renal disease was chronic glomerulonephritis in 9 patients and diabetes mellitus in 11 patients. Withdrawal from the study occurred because of death (n = 1) and patient's will (n = 1). In the control group, 9 men and 4 women completed the study. The underlying renal disease was chronic glomerulonephritis in 10 patients and diabetes mellitus in 3 patients. Withdrawal occurred because of death (n = 1), transfer to another hospital (n = 1), infections (n = 1), and patient's will (n = 2). Table 1 compares the clinical and laboratory parameters of the two groups of hemodialysis patients. There were no significant differences between the control and vitamin K 2 groups, except for the prevalence of diabetes mellitus.
Measurements
Venous blood samples were collected before hemodialysis for measurement of the serum levels of bone-specific alkaline phosphatase (B-ALP), intact osteocalcin (intact OC), cross-linked Nterminal telopeptide of type 1 collagen (NTx), calcium, phosphate, intact PTH, albumin, and OPG. B-ALP was measured by an immunoassay with a monoclonal anti-B-ALP antibody (Metra Biosystems, Mountain View, Calif., USA), intact OC was measured with the Osteocalcin Test Kokusai-F kit (International Reagents Corporation, Tokyo, Japan), NTx was measured by using an Osteomark NTx serum kit (Ostex International, Seattle, Wash., USA), and intact PTH was measured with the Nichols IRMA kit (Nichols Institute, San Juan Capistrano, Calif., USA). OPG was measured by using a human osteoprotegerin ELISA kit (BioVendor Laboratory Medicine, Brno, Czech Republic). The adjusted calcium level was calculated with Payne's formula [11] . B-ALP, intact OC, NTx, calcium, phosphate, and intact PTH were evaluated at baseline, as well as after 1, 3 and 12 months, while OPG was only measured at baseline and after 12 months.
Statistical Analysis
Results are shown as the mean 8 SD. The Mann-Whitney U test was employed to assess differences of continuous variables between the two groups, while the chi-square test was used for categorical data. The Wilcoxon signed rank test was also employed. In all analyses, p ! 0.05 was considered to indicate significance. Table 2 shows the changes of bone metabolism markers. Intact OC increased significantly after 1 month of vitamin K 2 administration. Although there was no significant increase in the serum levels of B-ALP and NTx after 3 months of vitamin K 2 administration, a significant increase was seen after 12 months. In the control group, these bone metabolism markers were unchanged throughout the study period. Table 3 shows the changes of adjusted calcium, phosphate, and intact PTH in the two groups, as well as the doses of oral calcium and the phosphate binder sevelamer hydrochloride. There was a significant increase of intact PTH after 12 months in the vitamin K 2 group, but not in the control group. In the vitamin K 2 group, the adjusted calcium level significantly increased after 3 months of treatment, while serum phosphate showed a significant decrease after 1 month. The dose of calcium carbonate was also increased significantly in vitamin K 2 group. In the control group, there were no significant changes of these parameters throughout the study period. The dose of sevelamer hydrochloride showed no significant changes throughout the study period in both groups. Table 4 displays the levels of OPG before the study and at 12 months. Serum OPG decreased after 12 months in the vitamin K 2 group, but the change was not significant. There was no significant change of OPG in the control group. 
Results
Discussion
In the present study, both bone formation markers (intact OC and B-ALP) and a bone resorption marker (NTx) were increased significantly by vitamin K 2 therapy. These changes of bone metabolism markers suggested that vitamin K 2 can improve bone remodeling in hemodialysis patients with low serum PTH levels.
Intact OC began to increase after 1 month of vitamin K 2 administration, and B-ALP also showed a significant increase after 12 months. Vitamin K 2 is an essential cofactor for site-specific carboxylation of osteocalcin and fully carboxylated osteocalcin (Gla-OC) binds to the calcium ions of hydroxyapatite [12] . It is widely known that Gla-OC is increased by vitamin K 2 therapy. In our previous study, the Gla-OC level was increased by at least 1.5-fold after 1 month of vitamin K 2 administration. Moreover, Shiraki et al. [13] have reported that 6 months of vitamin K 2 therapy increases intact OC as well as Gla-OC in postmenopausal osteoporosis patients. In this study, intact OC began to increase from one month and continued to increase for 12 months. These data indicate that vitamin K 2 enhanced the secretion of intact OC in hemodialysis patients with low intact PTH levels, and also stimulated bone formation.
In our patients, NTx also increased significantly after 12 months of vitamin K 2 therapy. NTx showed a decrease after 1 month of vitamin K 2 administration, but this was not significant. In the control group, the serum level of NTx was unchanged throughout the study period. NTx has been reported to be the most sensitive marker of bone resorption [14] , with serum or urinary NTx levels being decreased by effective antiresorptive therapy [15] . According to previous reports about osteoporosis patients and healthy athletes, administration of vitamin K 2 reduces bone resorption [16, 17] . Conversely, Shiraki et al. [13] reported that NTx excretion was increased in osteoporosis patients after 6 months of vitamin K 2 treatment. In our previous study, NTx also showed a significant increase with vitamin K 2 administration [9] . Vitamin K 2 has opposing effects that can promote or inhibit osteoclast activity. Vitamin K 2 inhibits osteoclastic bone resorption via its side chain and it also causes osteoclasts to undergo apoptosis [18, 19] . Conversely, osteocalcin production is stimulated by vitamin K 2 and it increases the secretion of osteopontin and fibronectin, thus promoting the activation of osteoclasts [20] . In the present study, osteocalcin showed a rapid increase after the start of vitamin K 2 administration, while the increase of NTx was seen after 12 months. This suggests that the stimulatory effect of vitamin K 2 on osteoclasts via osteocalcin became predominant over the direct inhibitory effect of vitamin K 2 itself at 12 months.
Adynamic bone disease is the most frequent type of renal osteodystrophy in hemodialysis patients. According to K/DOQI guideline 13C, adynamic bone disease in hemodialysis patients (as determined from either bone biopsy or an intact PTH level ! 100 pg/ml) should be treated by allowing the serum intact PTH level to rise in order to increase bone turnover [10] . There was a significant increase of intact PTH after 12 months in vitamin K 2 group. Oral administration of calcium carbonate was not regulated by our protocol, and the dose of oral calcium was increased significantly after 1 month in vitamin K 2 group. High-dose calcium supplementation led to an increase of serum calcium, but the serum intact PTH level was not suppressed even though the serum calcium level rose significantly. It has been considered that vitamin K 2 has no direct effect on parathyroid gland, but it is possible that the intact PTH level increased because bone metabolism was improved by vitamin K 2 therapy. If oral calcium intake had been limited, the effect of vitamin K 2 therapy might have been stronger. An intact PTH level ! 100 pg/ml is not only an indicator of adynamic bone disease, but is also a risk factor for higher all-cause mortality [4] . Previously, secondary hyperparathyroidism has been suggested to play a key role in the high prevalence of vascular calcification among hemodialysis patients. However, recent studies have indicated that low levels of PTH could also be associated with a higher risk of death in hemodialysis patients [21, 22] .
The relationship between bone mineralization markers and OPG has attracted attention recently, because OPG is an important physiological regulator of osteoclastogenesis and elevated OPG levels are associated with increased vascular calcification [4] . In this study, the OPG level showed a decrease after 12 months of vitamin K 2 therapy, but the change did not reach significance. There was also no significant change in the control group. We previously found that the serum OPG level showed a negative correlation with bone metabolism markers in hemodialysis patients [23] . Though we could not detect any strong effect of vitamin K 2 on serum OPG levels in this study, the decrease of OPG might have been involved in the changes of bone metabolism markers in the vitamin K 2 group.
Some limitations of the present study should be noted. First, we account with a relatively small size and this data needs confirmation in larger materials. Second, instead Vitamin K 2 and Adynamic Bone Disease Nephron Clin Pract 2011;117:c15-c19 c19 of random selection, the numbers of patients are different between vitamin K group and control group.
In conclusion, vitamin K 2 therapy improved bone remodeling in our patients. Vitamin K 2 is one of the candidates to treat the hemodialysis patients with an intact PTH level ! 100 pg/ml. Due to the small sample size and short observation period, our findings require confirmation in a larger patient population with longer follow-up.
